Scarica l'app Stockscreener
19.72
2.33%
-0.47
Dopo l'orario di chiusura:
19.72
Precedente Chiudi:
$20.19
Aprire:
$18.54
Volume 24 ore:
5.33M
Relative Volume:
4.99
Capitalizzazione di mercato:
$2.10B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-6.3819
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
+13.92%
1M Prestazione:
+45.00%
6M Prestazione:
+125.37%
1 anno Prestazione:
+28.89%
Intervallo 1D:
$18.32
$19.99
Intervallo di 1 settimana:
$17.45
$22.11
Portata 52W:
$6.50
$22.11
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
19.72 | 2.15B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Price action breakdown for Arcus Biosciences Inc.Weekly Investment Summary & Stock Timing and Entry Methods - newser.com
What dividend safety score for Arcus Biosciences Inc. stockJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - newser.com
Why Arcus Biosciences Inc. stock is rated strong buyJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
Automated trading signals detected on Arcus Biosciences Inc.2025 Risk Factors & Safe Capital Allocation Plans - newser.com
Risk adjusted return profile for Arcus Biosciences Inc. analyzed2025 Winners & Losers & Fast Entry High Yield Tips - newser.com
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Visual analytics tools that track Arcus Biosciences Inc. performance2025 Price Targets & High Accuracy Trade Alerts - newser.com
Analyzing recovery setups for Arcus Biosciences Inc. investorsWeekly Investment Recap & High Accuracy Trade Signal Alerts - newser.com
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Insider Selling - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported, And Analysts Assigned A US$29.60 Price Target - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
FY2025 EPS Estimates for RCUS Increased by Analyst - MarketBeat
Wedbush Increases Earnings Estimates for Arcus Biosciences - MarketBeat
HC Wainwright Has Positive Forecast for RCUS FY2025 Earnings - MarketBeat
Reversal indicators forming on Arcus Biosciences Inc. stockEarnings Beat & Safe Entry Zone Identification - newser.com
Why Arcus Biosciences Inc. stock appears on watchlistsJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 19,019 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 77,840 Shares of Stock - MarketBeat
Arcus Biosciences stock falls after pricing $250 million public offering By Investing.com - Investing.com Nigeria
Arcus Biosciences launches public offering of common stock By Investing.com - Investing.com Australia
Arcus Biosciences stock falls after pricing $250 million public offering - Investing.com
Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), TransMedics Group (TMDX) and Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences (RCUS) Announces Pricing Details for Recent Of - GuruFocus
Arcus Biosciences (RCUS) Announces Pricing Details for Recent Offering - GuruFocus
Arcus Biosciences falls after $250 mln stock sale - TradingView
Is Arcus Biosciences Inc. stock safe for risk averse investorsJuly 2025 Fed Impact & High Accuracy Investment Signals - newser.com
Arcus Biosciences Prices $250 Million Common Stock Offering - MarketScreener
Arcus Biosciences Inc. recovery potential after sell offMarket Risk Summary & Safe Entry Trade Signal Reports - newser.com
Arcus Biosciences prices $250 million public offering at $18.25 per share By Investing.com - Investing.com South Africa
RCUS Stock Quote Price and Forecast - CNN
Arcus Biosciences prices $250M offering - MSN
Should you hold or exit Arcus Biosciences Inc. nowJuly 2025 Reactions & Free Reliable Trade Execution Plans - newser.com
Arcus Biosciences (RCUS) Launches $250M Public Offering - GuruFocus
How moving averages guide Arcus Biosciences Inc. trading2025 Valuation Update & Growth-Oriented Investment Plans - newser.com
Arcus Biosciences prices $250 million public offering at $18.25 per share - Investing.com Australia
Arcus Biosciences says it announces pricing of $250 million public offering of common stock - MarketScreener
Arcus Biosciences (NYSE: RCUS) prices $250M stock offering of 13.7M shares - Stock Titan
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - MarketScreener
Arcus Biosciences (RCUS) Engages Investment Banks for New Offeri - GuruFocus
Arcus Biosciences falls on stock offering launch - TradingView
Arcus Biosciences launches public offering of common stock - Investing.com
Arcus Biosciences announces launch of public offering - MSN
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $56.00 at Citigroup - MarketBeat
Arcus Biosciences Announces Commencement of Public Offering of Common Stock - Stock Titan
Hedge Fund and Insider Trading News: Paul Tudor Jones, Berkshire Hathaway, Soros Fund Management, Citadel Investment Group, LMR Partners, Iridium Communications Inc (IRDM), Arcus Biosciences Inc (RCUS), and More - Insider Monkey
Goldman Sachs Maintains Neutral Rating on Arcus Biosciences (RCU - GuruFocus
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):